Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
J01DB04	HIKMA CEFAZOLIN	G	Cefazolin (sodium) - 1g	1,000mg	Injectable solution	215,015 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 150mg/ml	150mg/ml	Injectable solution	L.L
N05CD08	HIKMA MIDAZOLAM	G	Midazolam (HCl) - 5mg/ml	5mg/ml	Injectable solution	679,984 L.L
A03BB01	HISCOPINE (HYOSCINE BUTYL BROMIDE INJECTION)	G	Hyoscine butylbromide - 20mg/ml	20mg/ml	Injectable solution	3,217,159 L.L
B05AA01	HUMAN ALBUMIN "OCTAPHARMA" 20%	BioHuman	Albumin human - 20%	20%	Injectable solution	4,863,366 L.L
B05AA01	HUMAN ALBUMIN 20% SOLUTION	BioHuman	Albumin human - 20%	20%	Injectable solution	4,343,343 L.L
B05AA01	HUMAN ALBUMIN BEHRING 20%, LOW SALT	BioHuman	Albumin human - 20%	20%	Injectable solution	4,343,343 L.L
M01AE03	HUMFINE	G	Ketoprofen - 100mg/2ml	100mg/2ml	Injectable solution	3,514,148 L.L
B01AB01	HEPARINE MEDIS	G	Heparin sodium - 25,000UI/5ml	25,000UI/5ml	Injectable solution	6,853,597 L.L
B01AB01	HEPARINE SODIQUE PANPHARMA	G	Heparin sodium - 25,000IU/5ml	25,000IU/5ml	Injectable solution	6,134,641 L.L
B01AB01	HEPARIN-ORBUCELL	G	Heparin sodium - 25,000IU/5ml	25,000IU/5ml	Injectable solution	6,399,250 L.L
B01AB05	HEPAXANE 4000IU	BioTech	Enoxaparin sodium - 40mg/0.4ml	40mg/0.4ml	Injectable solution	3,559,839 L.L
B05XA03	HYPOTONIC SALINE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	149,393 L.L
B05XA03	HYPOTONIC SALINE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	163,184 L.L
B01AB12	HIBOR	G	Bemiparin Sodium - 2,500IU	2,500IU	Injectable solution	704,173 L.L
B01AB12	HIBOR	G	Bemiparin Sodium - 3,500IU	3,500IU	Injectable solution	1,029,383 L.L
B01AB12	HIBOR	G	Bemiparin Sodium - 5,000IU	5,000IU	Injectable solution	1,466,132 L.L
B01AB12	HIBOR	G	Bemiparin Sodium - 7,500IU	7,500IU	Injectable solution	2,198,526 L.L
L04AB04	HUMIRA	BioTech	Adalimumab - 40mg/0.4ml	40mg/0.4ml	Injectable solution	34,045,375 L.L
L04AB04	HYRIMOZ	BioTech	Adalimumab - 40mg	40mg	Injectable solution	19,536,163 L.L
L04AB04	HYRIMOZ	BioTech	Adalimumab - 40mg	40mg	Injectable solution	19,536,163 L.L
L04AB04	HYRIMOZ	BioTech	Adalimumab - 40mg/0.4ml	40mg/0.4ml	Injectable solution	52,871,023 L.L
L04AB04	HYRIMOZ	BioTech	Adalimumab - 40mg/0.4ml	40mg/0.4ml	Injectable solution	52,871,023 L.L
A10AB04	HUMALOG	BioTech	Insulin lispro - 100IU/ml	100IU/ml	Injectable suspension	1,988,887 L.L
A10AD01	HUMULIN 70/30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	701,486 L.L
A10AD04	HUMALOG MIX 50 KWIKPEN	BioTech	Insulin lispro solution - 50%, Insulin lispro protamine suspension - 50%	100IU/ml	Injectable suspension	3,950,897 L.L
A10AD04	HUMALOG MIX 25 KWIKPEN	BioTech	Insulin lispro solution - 25%, Insulin lispro protamine suspension - 75%	100IU/ml	Injectable suspension	3,950,897 L.L
A10AE01	HUMULIN N U-100	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	701,486 L.L
J07BC01	HEPATITIS-B VACCINE (r DNA) PAEDIATRIC	G	Hepatitis B, purified surface antigen adsorbed on aluminium hydroxide (Al+++) (0.25mg to 0.40mg) - 10mcg/0.5ml	10mcg/0.5ml	Injectable suspension	646,388 L.L
J07BC02	HAVRIX '1440'	B	Hepatitis A, inactivated, whole virus - 1,440 ELISA units/ml	1,440 ELISA units/ml	Injectable suspension	2,215,996 L.L